Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.

Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.

Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Lately, Pfizer (NYSE: PFE) ...

Bristol Myers Squibb recently closed at $48.79, rising 1.06%, easily outpacing the S&P 500’s 0.41% gain. Despite this, the ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune ...

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) ...

C3.ai AI witnessed a 12.3% rise in its share price during the after-hours trading session yesterday, following the release of ...

Combined with the last dividend raise by +3.3% in December 2024, building upon the 10Y growth profile at +5.27%, we believe ...

Garmin today announced SmartCharts, a dynamic aviation charting solution that will provide pilots with a simplified and ...

Bristol-Myers Squibb Company's undervaluation offers over 20% upside potential despite headwinds. Click here to find out why ...

Plenge currently works at PhRMA Foundation, as Director and Bristol Myers Squibb Co., as Chief Research Officer, Head-Research & EVP from 2019. Dr. Plenge also formerly worked at Translate Bio, Inc., ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...